ArticleThe Journal of infectious diseases2026
Increased In-Hospital Mortality in Immunocompromised Individuals Hospitalized With COVID-19 During the Global Pandemic: A Multinational Cohort Study in the EuCARE Project.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundAlthough coronavirus disease 2019 (COVID-19) is no longer a public health emergency, it remains the most prevalent circulating infectious-like illness in Europe. Whether immunocompromising conditions (ICCs) still carry increased mortality risk during the Omicron era is unclear.
methodsWe conducted a cohort study across EuCARE sites in 8 countries among adults admitted to hospital with COVID-19 between 2020 and 2023. ICCs and COVID-19 pneumonia at hospitalization were defined using clinical information and ICD-10 codes. Logistic regression and counterfactual mediation analysis was used to compare 28-day in-hospital mortality risk associated with ICCs using COVID-19 pneumonia and vaccination at hospital entry as intermediates. Proportion of the total effect of ICCs mediated and the controlled direct effects (CDEs) were calculated. We also formally tested for interaction between SARS-CoV-2 variants and ICCs for mortality risk.
resultsA total of 42 488 individuals were included, of whom 1675 (3.9%) had an ICC. Fifty-five percent were male, and the median age was 67 (IQR, 52-79) years. Overall, 4344 (10.2%) individuals died in hospital. ICCs were associated with increased mortality (OR, 1.49 [95% CI, 1.25-1.79]), with no evidence for an attenuation during the Omicron phase (P value for interaction = .60). Mediation analyses showed that the total effect of ICCs was mediated by vaccination but only weakly by pneumonia. With Omicron, the excess mortality associated with ICC was higher under the scenario that everyone in the cohort was to develop COVID-19 pneumonia (CDE, 1.22 [95% CI, .09-1.65]).
conclusionsICC remains a significant risk factor for in-hospital death, even during the Omicron era, particularly if the infection led to the development of pneumonia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.